Identifying regulators of chronic myeloid leukaemic (CML) stem cell quiescence and discovering effective novel therapies for CML relapse

Identifying regulators of chronic myeloid leukaemic (CML) stem cell quiescence and discovering effective novel therapies for CML relapse

<p>Chronic myeloid leukaemia (CML) is a myeloproliferative neoplasm characterised by the presence of Philadelphia (Ph) chromosome. The standard treatment is tyrosine kinase inhibitors (TKI), while they achieve remission in many patients, the majority will relapse on cessation of therapy. This...

Descrizione completa

Dettagli Bibliografici
Autore principale:	Xu, Z
Altri autori:	Mead, A
Natura:	Tesi
Lingua:	English
Pubblicazione:	2022

Documenti analoghi

Progress with interferon in CML--results of the MRC UK CML III study.
di: Shepherd, P, et al.
Pubblicazione: (1996)

Targeting a chronic problem: elimination of cancer stem cells in CML.
di: Nerlov, C
Pubblicazione: (2009)

BONE-MARROW TRANSPLANTATION (BMT) FOR CHRONIC MYELOID-LEUKEMIA (CML) USING MATCHED UNRELATED DONORS
di: Mackinnon, S, et al.
Pubblicazione: (1988)

BONE-MARROW TRANSPLANTATION (BMT) FOR CHRONIC MYELOID-LEUKEMIA (CML) USING MATCHED UNRELATED DONORS
di: Mackinnon, S, et al.
Pubblicazione: (1988)

Imatinab mesylate treatment in Chronic Myeloid Leukemia (CML)- understanding the fundamental pharmacokinetic and pharmacogenetic mechanisms for variation in response
di: Ankathil, Ravindran
Pubblicazione: (2016)

BONE-MARROW TRANSPLANTATION USING UNRELATED DONORS FOR CML IN CHRONIC PHASE
di: Cullis, J, et al.
Pubblicazione: (1991)

CML ENGAGEMENT IN ENGLISH COMPETENCY FOR TVET EDUCATORS
di: Nor Yazi, Khamis, et al.
Pubblicazione: (2024)

UNLEASHING THE POWER OF CML THE JOURNEY TO EKSA AWARD
di: Fathiah Izzati, Mohammad Fadzillah, et al.
Pubblicazione: (2024)

BONE-MARROW TRANSPLANTATION FOR CHRONIC PHASE CML - THE ROLE OF T-CELL DEPLETION IN 1988
di: Mackinnon, S, et al.
Pubblicazione: (1988)

CML CELEBRATES MALAYSIAN HEROES AT “SPEAK UP!” 2024
di: Wan Noor Farah, Wan Shamsuddin, et al.
Pubblicazione: (2024)

TechTIM By CML at The National Science Week Carnival 2023
di: Hafizoah, Kassim, et al.
Pubblicazione: (2023)

Thioguanine used in maintenance therapy of chronic myeloid leukaemia causes non-cirrhotic portal hypertension. Results from MRC CML. II. Trial comparing busulphan with busulphan and thioguanine.
di: Shepherd, P, et al.
Pubblicazione: (1991)

Autografting for patients with CML in chronic phase: an update. Hammersmith BMT Team LRF Centre for Adult Leukaemia.
di: Hoyle, C, et al.
Pubblicazione: (1994)

Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML
di: Winter, Georg E, et al.
Pubblicazione: (2014)

Immunoresponse to Wilms Tumor antigen-1 (WT-1) in CML patients.
di: Bellantuono, I, et al.
Pubblicazione: (2000)

Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study
di: Milojkovic, D, et al.
Pubblicazione: (2020)

MATCHED UNRELATED DONOR BMT FOR CML - COMPARISON OF EXVIVO AND INVIVO T-CELL DEPLETION
di: Cullis, J, et al.
Pubblicazione: (1992)

CNL and aCML should be considered as single entity based on molecular profiles and outcomes
di: Carreño-Tarragona, G, et al.
Pubblicazione: (2022)

Immunohistochemical study of N-epsilon-carboxymethyl lysine (CML) in human brain: relation to vascular dementia
di: Southern, L, et al.
Pubblicazione: (2007)

Immunohistochemical study of N-epsilon-carboxymethyl lysine (CML) in human brain: relation to vascular dementia
di: Southern, L, et al.
Pubblicazione: (2007)

INTERFERON-ALPHA(IFN-ALPHA) PROLONGS SURVIVAL FOR PATIENTS WITH CML IN CHRONIC PHASE - PRELIMINARY-RESULTS OF THE UK MRC RANDOMIZED MULTICENTER TRIAL
di: Allan, N, et al.
Pubblicazione: (1994)

A randomised comparison of low or high dose IFN-alpha in newly diagnosed CML patients shows no difference in major cytogenetic response rate or survival between the two groups - Results of MRC CML V and HOVON 20 trials.
di: Shepherd, P, et al.
Pubblicazione: (2001)

Empowering Educators Practical Instructional Workshop at CML, UMPSA enhances Instructional Approaches for the 21st Century
di: Hafizoah, Kassim, et al.
Pubblicazione: (2024)

Telomere length shortening in CML is associated with reduced time to accelerated phase but does not influence overall survival.
di: Boultwood, J, et al.
Pubblicazione: (1999)

The long term outcome of the patients with chronic myeloid leukemia (CML) who have achieved complete cytogenetic response (CCgR) to interferon-alpha (IFN alpha). A collaborative European study of 317 cases.
di: Bonifazi, F, et al.
Pubblicazione: (2001)

Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse.
di: Apperley, J, et al.
Pubblicazione: (1986)

Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia.
di: Waldmann, H, et al.
Pubblicazione: (1987)

Angiocrine signals regulate quiescence and therapy resistance in bone metastasis
di: Singh, A, et al.
Pubblicazione: (2019)

Cellular Mechanisms and Regulation of Quiescence
di: Marescal, Océane, et al.
Pubblicazione: (2021)

10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN A SINGLE UK CENTRE: COMPARISON WITH PRE-TKI ERA AND EVALUATION OF 2013 ELN GUIDELINES
di: Khan, D, et al.
Pubblicazione: (2014)

BCR-ABL1 kinase domain mutation screening using next generation sequencing in CML and Ph plus ALL patients
di: Kizilors, A, et al.
Pubblicazione: (2019)

Nephrotic Syndrome in a Patient with Relapsed of Chronic Myeloid Leukemia after Peripheral Blood Stem Cell Transplantation
di: Bee, P.C., et al.
Pubblicazione: (2008)

Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia.
di: Bradbury, C, et al.
Pubblicazione: (2014)

Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia
di: Kinstrie, R, et al.
Pubblicazione: (2016)

Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia.
di: Gupta, M, et al.
Pubblicazione: (2008)

An Slfn2 mutation causes lymphoid and myeloid immunodeficiency due to loss of immune cell quiescence.
di: Berger, M, et al.
Pubblicazione: (2010)

5 ' Azacitidine in Combination with Valproic Acid Induces Complete Remissions in Patients with Advanced Acute Myeloid Leukaemia but Does Not Eradicate Clonal Leukaemic Stem/Progenitor Cells.
di: Craddock, C, et al.
Pubblicazione: (2008)

Clonal structures of leukaemia stem cell populations in myeloid blast phase chronic myeloid leukaemia
di: Karamitros, D, et al.
Pubblicazione: (2016)

Phenotypic evolutionary models in stem cell biology: replacement, quiescence, and variability
di: Mangel, M, et al.
Pubblicazione: (2008)

Phenotypic evolutionary models in stem cell biology: replacement, quiescence, and variability.
di: Mangel, M, et al.
Pubblicazione: (2008)